Paper Details

  1. Home
  2. Paper Details

Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.

Author: , AgugliaUmberto, BossioRoberto Bruno, Brescia MorraVincenzo, CapacchioneAntonio, ChisariClara Grazia, MarzioloRoberto, PattiFrancesco, ValentinoPaola, ZappiaMario, ZimatoreGiovanni Bosco

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study discusses the flu-like syndrome (FLS) associated with subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) treatment for relapsing multiple sclerosis (RMS). FLS occurs in 75% of patients, and there are no recommendations on whether evening or morning administration could induce better or worse FLS.
Paper Details　
Original Abstract of the Article :
Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could ind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00415-020-09771-x

データ提供：米国国立医学図書館（NLM）

Evening vs. Morning: When to Take Interferon Beta-1a for Multiple Sclerosis?

The world of multiple sclerosis (MS) treatment is a vast desert, and researchers are constantly searching for oases of better therapies. This study dives deep into the sand, exploring the optimal time to administer subcutaneous interferon beta-1a (IFN-β1a SC), a common treatment for relapsing MS.

IFN-β1a SC is like a camel carrying a precious cargo of relief for MS symptoms, but it can sometimes cause unpleasant side effects, like a flu-like syndrome (FLS) that can be quite the camel-back breaker for some patients. The researchers wondered if administering the medication in the evening or morning might affect the likelihood of FLS.

They discovered that while there are no concrete recommendations for evening or morning administration, it's crucial to understand that FLS is a common side effect of IFN-β1a SC, affecting about 75% of patients. This study encourages further exploration to find the best time to administer this medication, making the journey through MS a little smoother for patients.

What Does This Mean for Patients?

It's important to talk to your doctor about the best time to take interferon beta-1a for your individual needs. They can help you navigate the desert of MS treatment and find the optimal time to take your medication, helping you find your own oasis of comfort.

Health Impacts and Lifestyle Tips

While this research isn't conclusive, it highlights the importance of understanding the potential side effects of medications. If you're experiencing FLS, talk to your doctor about possible solutions. It's essential to keep your doctor informed about any side effects you experience, and they can work with you to manage these issues and find a solution that works best for you.

Dr.Camel's Conclusion

This study is like a lone camel traversing a vast desert, searching for a better understanding of MS treatment. While it doesn't offer a definitive answer, it reminds us of the importance of individualizing treatment plans and the ongoing need for further research. The journey through MS is a long one, but with continued exploration and open communication with your doctor, you can find your own oasis of health and well-being.

Date :
  1. Date Completed 2021-03-17
  2. Date Revised 2021-03-17
Further Info :

Pubmed ID

32140867

DOI: Digital Object Identifier

10.1007/s00415-020-09771-x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.